GlaxoSmithKline Warned about Misleading Marketing in 2001
The Food and Drug Administration warned GlaxoSmithKline in 2001 that it needed to halt playing down the risk of heart attacks connected with taking Avandia, according to a Bloomberg News article ("U.S. FDA Warned Glaxo in 2001 About Avandia Marketing," May 24, 2007).
According to this report, a diabetes expert submitted a letter to the FDA a year earlier, airing concerns about Glaxo's perceived abuse of clinical trial data in regard to the cardiovascular safety of Avandia.
Following this warning, says Bloomberg, the FDA sent Glaxo a letter asking that its marketers stop denying or minimizing the increased risk of heart attacks and other cardiovascular events.
However, the article says, "Glaxo didn't notify doctors or patients of the possible increase in risks."
If you or a loved one has suffered cardiac complications after taking Avandia, you need the guidance of an experienced drug attorney. Get a free case review by filling out the form below.
Click To Talk To Us Online
Experts Cite Risks Federal Scientist: Pull Avandia From the Market Because of Heart Risks
Panel Convenes, Scientist Recommends Taking Avandia off the Market
NEJM Study Avandia Drug NEJM Study | Weitz & Luxenberg
Study on Rosiglitazone (Avandia) Medication and Risk of Cardiac Issues
Diabetes Drugs Avandia Sales Drop as the Public Turns to Alternatives Such as Actos
Like Avandia, Actos sales reflect use to Treat Type 2 Diabetes